Form 4: BioCardia Director Stertzer Acquires Stock Options
SEC Form 4 Filing
Director Simon H. Stertzer acquired stock options in BioCardia, Inc. on October 11, 2024.
Summary
- On October 11, 2024, Simon H. Stertzer, a director of BioCardia, Inc., acquired stock options to purchase 829 shares of common stock at an exercise price of $2.65.
- The options vest 100% on the one-year anniversary of the grant date, contingent upon continued service.
- Following the transaction, Stertzer directly owns 3,573 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors.
Stakeholder Impact
- The transaction provides information to shareholders about director's holdings and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of stock option grant and transaction. |
| 10/11/2034 | Expiration date of the stock options. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, derivative securities, BioCardia, BCDA, insider trading, Stertzer, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.